Home About Us Technology Product & Services News & Events Contact Us
Company Mission

Vivo Biosciences Inc. (VBI), an early stage biotech company founded in 2004, has developed new ‘all-human’ bioassay platforms for preclinical research, drug discovery and therapeutics. The company relies on its patented HuBiogel™ technology which emulates the biology of normal and disease tissues in vitro. A series of 3-D or Mini-tumor bioassay systems are developed for rapid analysis of drug efficacy, toxicity and therapy prediction, the major bottlenecks of current drug development pipeline. This high-value technology is offered worldwide to academic, commercial and government institutions.


VBI Management and Board of Directors

Raj Singh, PhD, President, CEO, CSO and Board Member
Dr. Singh, a well recognized cancer researcher,  is the founder of Vivo Biosciences and the principal developer of the company’s HuBiogel technology. He has established the proprietary protocols for HuBiogel production and bioassay systems. He has validated the tumorigenesis and angiogenesis assay models and created new 3D tissue-like functional models for drug discovery, therapeutic and toxicity research. He has received many significant top-scored SBIR and STTR grants and contracts. With more than 50 publications including a recent book chapter, he also has several US and International technology patents issued and pending.


Alan H. Dean, Board Member
Managing Partner, Fund Operations of Greer Capital Advisors (GCA). Mr. Dean has more than 20 years’ experience in all aspects of technology transfer, in both the non-profit and for-profit sectors.  Prior to joining GCA, Mr. Dean was Director of the University of Texas Health Science Center in San Antonio's Office of Technology Transfer, where he played a prominent role in the formation of numerous successful technology companies, and in greatly elevating licensing productivity.  Mr. Dean was also head of technology commercialization at Southern Research Institute, an institution known for its oncology drug discoveries, and led the team responsible for licensing Institute inventions and forming technology spin-offs.  He co-founded the drug-delivery company, Southern BioSystems, Inc., which was later acquired by a public company.   Mr. Dean sits on the board of CardioSpectra, Inc., one of Scout Health Care Fund's portfolio companies as well as BioDtech, one of the Birmingham Technology Fund's portfolio companies. 


Lawrence DeLucas, PhD, OD, DSc (hon), Board Member
Professor and Director of Center for Biophysical Sciences & Engineering, Director and a Senior Scientist at the University of Alabama at Birmingham Comprehensive Cancer Center X-ray Crystallography Facility, and a Professor in the Schools of Optometry, Biochemistry, and Physiology and Biophysics.  He is a recipient of the  UAB distinguished faculty award and the State of Alabama Howard Heflin Statesmanship Award for Technology Innovation.  Dr. DeLucas also served as an NASA astronaut serving as the payload specialists aboard the space shuttle Columbia and as the NASA Chief Scientist for the International Space Station .  Dr. DeLucas is a founding member of Vivo Biosciences Board of Directors. As a distinguished scientist, he serves as member of multiple biotechnology company boards.


Philip W. Faris, Jr., Board Member
CEO and managing partner at ProSavant International.  Faris has a distinguished track record of building market-leading companies in emerging medical markets and has successfully performed as CEO for over three decades in start-up, early stage, and high-growth organizations. He is currently CEO and managing partner at ProSavant International, a strategic consulting firm for the medical device and biotechnology spaces and is Executive Chairman of Innovative Trauma Care, Inc., an early stage medical device company focused on the treatment of major challenges in trauma care at the point of injury. He also serves on the Executive Committee of BiomedSA, a non-profit organization promoting the bioscience industry in San Antonio, Texas. Through his career, Faris has acted as CEO and Director at Vidacare Corporation, VidiMedix Corporation, Trestle Corporation, Diatek Corporation and many other medical device,  biotechnology and health care companies.


Lawrence W. Greer, Board Member
Senior Managing Partner and founder of Greer Capital Advisors. Dr. Greer has directed the S.C.O.U.T. Healthcare Fund and the Birmingham Technology Fund as its General Partner. He is directly involved with management, operational oversight, strategic planning, capitalization events and industry negotiations. He presently serves on the Advisory Committee of the New Virginia Capital Partners Fund, LP and the Investment Committee of the Whitecap Alabama Growth Fund I and II, as well as General Partner to the Birmingham Technology Fund, LLC which he raised in 2006.  Dr. Greer also serves as Chairman of the Audit Committee of Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX), a company he participated in founding in 1999 and a portfolio company of the S.C.O.U.T. Fund.  Dr. Greer holds board director seats for many of the Fund’s portfolio companies and several start-up tech transfer companies.

Home / About Us / Technology / Products & Services / News & Events / Contact Us
© 2012 All Rights Reserved. Vivo Biosciences, Inc. Office 1+205-930-0001